WuXi Biologics breaks ground on CRDMO Center in Singapore
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
The facility will manufacture tablets, capsules, and injections for the oncology segment
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Subscribe To Our Newsletter & Stay Updated